Site icon pharmaceutical daily

Sarah Cannon to Present Latest Cancer Research Insights at 2019 American Society of Clinical Oncology’s Annual Meeting

NASHVILLE, Tenn.–(BUSINESS WIRE)–Today, Sarah
Cannon
announced that it will present its latest cancer research
insights through more than 100 abstracts and presentations at the American
Society of Clinical Oncology’s
(ASCO®) Annual Meeting hosted in
Chicago, from May 31-June 4, 2019. The ASCO® Annual Meeting brings
together more than 40,000 cancer experts from around the world to review
the latest research and discuss this year’s theme of “Caring for Every
Patient, Learning from Every Patient.” Sarah Cannon experts will
participate in a number of presentations and educational sessions
focused on immunotherapies, including cellular therapy, and targeted
investigational agents that are transforming the delivery of cancer care
for patients.

“The research presented at this year’s Annual Meeting will highlight
Sarah Cannon’s involvement in the latest CAR T-Cell Therapy approaches,
bispecific antibodies, novel targeted therapies as well as personalized
cancer vaccines. We continue to be excited about the developments being
made in individualized cancer therapies and the potential impact for
patients worldwide,” said Howard
A. “Skip” Burris, III, MD
, President of Clinical Operations and
Chief Medical Officer at Sarah Cannon. Dr. Burris will serve as the
ASCO® President for the 2019-2020 term, and will be inducted into his
position on Monday, June 3, during the Annual Meeting.

A number of Sarah Cannon’s presentations will focus on insights from
more than 50 phase 1 studies, which include novel immunotherapy
combinations and CAR T-Cell, as well as mutation-targeted agents.

An oral presentation titled “Safety and Preliminary Antitumor
Activity of U3-1402: A HER3-Targeted Antibody Drug Conjugate in EGFR
TKI-Resistant, EGFRm NSCLC
,” will feature the work of Melissa
Johnson, MD
, an investigator on the trial. Additionally, Sarah
Cannon’s work, under the leadership of Gerald
Falchook, MD
, on the phase I trial investigating the targeted
therapy KRASG12C will be highlighted in an oral presentation at the
meeting. The phase 1 dose escalation study of the ERK inhibitor
LY3214996 will also be highlighted in an oral presentation, featuring
the work of Johanna
Bendell, MD
, and Manish
Patel, MD
.

Lowell
Hart, MD
, will highlight the latest in novel biologics through an
oral presentation on the “Effect of Trilaciclib, a CDK 4/6 Inhibitor,
on Myelosuppression in Patients with Previously Treated Extensive-Stage
Small Cell Lung Cancer Receiving Topotecan
.” Sarah Cannon’s work in
cellular therapy, under the leadership of William
Donnellan, MD
, will be showcased in an oral presentation on the
phase I results of KTE-X19 in adult patients with relapsed/refractory
acute lymphoblastic leukemia.

Additionally, Sarah Cannon investigators are presenting noteworthy
studies as first authors through the following presentations:

Sarah Cannon experts will also share insights through education sessions
and oral presentations including:

For a full listing of all presentations authored by Sarah Cannon
investigators, visit sarahcannon.com/asco.

The researchers represent Sarah Cannon’s global network of strategic
sites:

Colorado
Blood Cancer Institute
Sarah
Cannon Research Institute at Florida Cancer Specialists
Sarah
Cannon Research Institute at HCA Midwest Health (Kansas City)
, Sarah
Cannon Research Institute at HealthONE (Denver)
, Sarah
Cannon Research Institute at Tennessee Oncology
, Sarah
Cannon Research Institute – United Kingdom
, and The
Stephenson Cancer Center at the University of Oklahoma
.

About Sarah Cannon Research Institute

Sarah Cannon Research Institute is the research arm of HCA Healthcare’s
Cancer Institute, Sarah Cannon. Focused on advancing therapies for
patients, it is one of the world’s leading clinical research
organizations conducting community-based clinical trials throughout the
United States and United Kingdom. A leader in drug development, Sarah
Cannon has led more than 370 first-in-human clinical trials since its
inception in 1993, and has been a clinical trial leader in the majority
of approved cancer therapies over the last 10 years. Additionally, Sarah
Cannon offers management, regulatory, and other research support
services for drug development and industry sponsors as well as strategic
investigator sites through its contract research organization (CRO),
Sarah Cannon Development Innovations. For more information, visit sarahcannon.com.

Contacts

Samantha Maxwell
samantha.maxwell@sarahcannon.com

Exit mobile version